x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012217
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat, Monkey |
| Applications | WB, IP, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu55 of human LAMTOR5/HBXIP protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | LAMTOR5 |
| UniProt No. | O43504 |
| Gene ID | 10542 |
| Gene Description | Late endosomal/lysosomal adaptor and MAPK and MTOR activator 5 is an essential component of the ragulator protein complex that is encoded by the HBXIP gene. The ragulator complex also includes LAMTOR1/C11orf59, LAMTOR2/ROBLD3, LAMTOR3/MAPKSP1, and LAMTOR4/C7orf59. Research studies demonstrate that the ragulator complex localizes to the lysosomal membrane and is essential for the lysosomal localization of Rag GTPases and mTORC1 as well as the subsequent activation of mTORC1 in response to amino acid signaling. Additional research studies indicate that HBXIP regulates hepatitis B virus x protein activity and is a transcription coactivator involved in the proliferation and migration of breast cancer cells. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
